Scotoma Reduction in AMD Patients Treated With Ranibizumab (SALVAGE)

Retina Research Foundation

Status and phase: Completed; Phase 2; Phase 1

Conditions: Macular Degeneration

Treatments: Drug: intravitreal injection Lucentis (ranibizumab)

Study type: Interventional

Funder types: Other

Identifiers

NCT00467935

FVF3933

Details and patient eligibility

About

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Full description

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Enrollment: 20 estimated patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• BCVA < 20/320
• Disciform macular degeneration wiht exudation

Exclusion criteria

• Non-amd CNV

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)